Why Investors Are Buying NeuroSense Therapeutics Stock Today


Shares of clinical-stage biotech company NeuroSense Therapeutics Ltd NRSN are ripping higher Thursday morning after the company reported positive final results from its Alzheimer's biomarker study.

What Happened: Preliminary results from a study evaluating the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD), showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group.

Based on the "encouraging" results, NeuroSense has expanded the study with a larger healthy control group to further validate the preliminary reading.

NeuroSense's platform combination therapy technology has already shown a statistically significant reduction of TDP-43 in a Phase 2a clinical trial biomarker study in amyotrophic lateral sclerosis (ALS), and is currently being evaluated in a Phase 2b ALS double-blind clinical trial. 

NeuroSense believes its preliminary results suggest the potential efficacy of NeuroSense's platform technology in Alzheimer's disease. The company said it plans to start a Phase 2 double-blind proof-of-concept study in Alzheimer's disease in the first half of 2023.

NeuroSense is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.

Check This Out: Best Biotech Stocks Right Now

NRSN Price Action: NeuroSense has a 52-week high of $8.18 and a 52-week low of $1.07.

The stock was up 73.8% at $2.19 at the time of writing, according to Benzinga Pro.

Photo: Alexandra_Koch from Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksMoversGeneralAlzheimer’s Diseasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!